Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case–control studies of incidence and associated risk factors
Lactic acidosis is a rare complication of linezolid (LZD) therapy, and its incidence and risk factors remain unknown. This study aimed to compare the incidence of LZD-associated lactic acidosis (LALA) and vancomycin (VAN)-associated lactic acidosis (VALA) and investigate the risk factors for LALA.
We performed a retrospective cohort study using propensity score-matched analyses comparing the incidence of lactic acidosis between LZD and VAN therapy. We included adult patients administered LZD or VAN between April 2014 and March 2016 and extracted patient baseline data. In a case–control study, we identified the risk factors of lactic acidosis in patients treated with LZD.
We identified 94 and 313 patients who were administered LZD and VAN, respectively. The incidence of lactic acidosis after LZD and VAN therapy was 10.6 and 0.3%, respectively. After propensity score-matched analyses, the incidence of lactic acidosis with LZD therapy was significantly higher than that with VAN therapy [10.0% (8/80) vs. 0% (0/80), respectively; risk difference, 0.1; 95% confidence interval (CI), 0.03–0.17; p = 0.004]. In a case–control study, 10 patients with LALA were matched to 20 non-lactic acidosis patients by age and sex. Patients with LALA were more likely to have renal insufficiency than non-lactic acidosis patients that were in the univariate analysis (odds ratio, 7.4; 95% CI, 1.0–84.4; p = 0.02).
This study indicates that LALA occurs more frequently than VALA does and is associated with renal insufficiency. Therefore, close monitoring of kidney function and serum lactate is recommended during LZD therapy.
KeywordsLinezolid-associated lactic acidosis Vancomycin-associated lactic acidosis Propensity score-matched analysis Renal insufficiency
We would like to thank Editage (www.editage.com) for the English language editing and Publication Support.
NM, YK, and SB contributed to conception and design of the study. All authors contributed to acquisition of data and data analysis. NM mainly contributed to drafting this article. All authors contributed to the critical revision and gave final approval of the manuscript.
Compliance with ethics standards
This study was approved by the NTMC ethics committee (IRB protocol number: R16-102) and was carried out in accordance with the Declaration of Helsinki principles. The need for patient consent was waived owing to the retrospective nature of the study. Information about the study was made public through postings on facility notice boards and webpages. Patients and their representative agents had the right to refuse study participation.
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Beekmann SE, Gilbert DN, Polgreen PM (2008) Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey. Diagn Microbiol Infect Dis 62(4):407–410. https://doi.org/10.1016/j.diagmicrobio.2008.08.009 CrossRefPubMedGoogle Scholar
- 15.Del Pozo JL, Fernandez-Ros N, Saez E, Herrero JI, Yuste JR, Banales JM (2014) Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism. Antimicrob Agents Chemother 58(7):4227–4229. https://doi.org/10.1128/AAC.02856-14 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Tanaka M, Cabrera VM, González AM, Larruga JM, Takeyasu T, Fuku N, Guo LJ, Hirose R, Fujita Y, Kurata M, Shinoda K, Umetsu K, Yamada Y, Oshida Y, Sato Y, Hattori N, Mizuno Y, Arai Y, Hirose N, Ohta S, Ogawa O, Tanaka Y, Kawamori R, Shamoto-Nagai M, Maruyama W, Shimokata H, Suzuki R, Shimodaira H (2004) Mitochondrial genome variation in eastern Asia and the peopling of Japan. Genome Res 14(10a):1832–1850. https://doi.org/10.1101/gr.2286304 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Song T, Lee M, Jeon H-S et al (2015) Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBioMedicine 2(11):1627–1633. https://doi.org/10.1016/j.ebiom.2015.09.051 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Achilli A, Rengo C, Magri C, Battaglia V, Olivieri A, Scozzari R, Cruciani F, Zeviani M, Briem E, Carelli V, Moral P, Dugoujon JM, Roostalu U, Kivisild T, Bandelt HJ, Richards M, Villems R, Santachiara-Benerecetti AS, Semino O, Torroni A (2004) The molecular dissection of mtDNA haplogroup H confirms that the Franco-Cantabrian glacial refuge was a major source for the European gene pool. Am J Hum Genet 75(5):910–918. https://doi.org/10.1086/425590 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K (2010) Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrobial Agents 36(2):179–181. https://doi.org/10.1016/j.ijantimicag.2010.02.019 CrossRefGoogle Scholar
- 23.Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K (2013) High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 68(9):2128–2133. https://doi.org/10.1093/jac/dkt133 CrossRefPubMedGoogle Scholar